Pembrolizumab is a PD-1 inhibitor, and common adverse reactions associated with PD-1 and PD-L1 blockers include pneumonitis, myalgia, hypothyroidism, gastrointestinal reactions, arthralgia, and vitiligo. This evidence concerns the gene CD274 and hypothyroidism.